Qnovia develops and commercializes proprietary inhalation device technologies centered on its RespiRx™ platform, an orientation-agnostic, portable vibrating mesh nebulizer. Its lead asset is the RespiRx™ Nicotine Inhaler (QN-01), a prescription inhaled smoking cessation therapy that has demonstrated clinical proof-of-concept in a first-in-human Phase 1 study and received FDA IND clearance. The company plans to advance QN-01 beyond Phase 1 and pursue a Marketing Authorization Application (MAA) submission to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in 2026, aiming to accelerate commercialization in the UK. Qnovia will use recent proceeds to support clinical, regulatory, and commercial development of QN-01 and to evaluate additional therapeutic indications for its platform. Founded in 2018, the company highlights opportunities to apply its device technology to asthma, COPD, vaccine delivery, pain management, generics, and select investigational drugs. Qnovia is led by CEO Brian Quigley and was founded by Mario Danek. Qnovia develops proprietary inhalation device technologies, centering on its RespiRx platform described as the first orientation-agnostic, portable vibrating mesh nebulizer. The company’s initial clinical focus is nicotine replacement therapy (NRT) with plans to expand into other cardiopulmonary and therapeutic indications including asthma, COPD, vaccine delivery, and pain management. Qnovia sees opportunities to apply its platform to several generic and investigational drugs to improve patient outcomes. The company raised $17 million in a Series A and will use the proceeds to advance its NRT drug candidate through an IND submission and begin human clinical trials in 2023. Qnovia plans to initiate a Phase 1 study for NRT once the FDA approves its IND application. The company was founded by Mario Danek in 2018 and is based in Los Angeles.

Total raised

$33M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2024